VSTM2L and cancer: High VSTM2L expression was associated with shorter OS in BLCA, KIRC, OV, STAD, THYM, UCEC, and UVM but predicted better outcome in KIRP (Figure 2A); VSTM2L expression had no prognostic value in the OS of other cancers (Supplementary Figure S2).